Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
PEMBROLIZUMAB
MERCK CANADA INC
L01FF02
PEMBROLIZUMAB
50MG
POWDER FOR SOLUTION
PEMBROLIZUMAB 50MG
INTRAVENOUS
2.3ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0156910001; AHFS:
CANCELLED POST MARKET
2019-12-04
_KEYTRUDA® (pembrolizumab) _ _Page 1 of 248_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KEYTRUDA® pembrolizumab solution for infusion 100 mg/4 mL vial Antineoplastic agent, monoclonal antibody KEYTRUDA®, indicated for: • Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT. • Adult and pediatric patients with refractory Primary Mediastinal B-cell Lymphoma (PMBCL) or who have relapsed after 2 or more lines of therapy, as monotherapy. • Adult patients with locally advanced unresectable or metastatic urothelial carcinoma, as monotherapy, who are not eligible for any platinum-containing chemotherapy. • Adult patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy. • Adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) o colorectal cancer whose tumours have progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy, or o endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy. • Adult patients in combination with lenvatinib with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. has been issued market authorization WITH CONDITIONS, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for KEYTRUDA® please refer to Health Canada’s No Baca dokumen lengkap